KCT0001107进行中（未招募）未知
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly Korea0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Key Inclusion Criteria
- •- Histologically or cytologically confirmed squamous NSCLC
- •- Stage IV disease at time of study entry based on AJCC 7th edition
- •- Measurable disease at time of study entry as defined by RECIST 1.1
- •- Archived or recent tumor tissue (minimum of 5 unstained tissue slides or a paraffin-embedded tissue
- •block) available for analysis of EGFR protein expression by IHC and other biomarker assessments
排除标准
- •Key Exclusion Criteria
- •- Nonsquamous NSCLC
- •- Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies
- •targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor
- •- Previous chemotherapy for NSCLC
- •- Major surgery or received any investigational therapy in the 4 weeks prior to randomization
- •- Chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions,
- •which is allowed)
- •- Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants
- •(patients who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic
- •and no longer require treatment with steroids or anticonvulsants, are eligible)
研究者
相似试验
招募中
2 期
A Randomized Phase 2 Study of TRK-950 when Used in Combination withRamucirumab and Paclitaxel in Patients with Gastric CancerGastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaJPRN-jRCT2031230319Mori Yoshitaka146
进行中（未招募）
1 期
A Study in advanced squamous non small cell lung cancerStage IV Squamous Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 16.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003214-13-DEEli Lilly and Company189
进行中（未招募）
不适用
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell LymphomaEUCTR2009-012280-34-CZJanssen-Cilag International N.V.164
进行中（未招募）
1 期
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell Lymphomaon-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaMedDRA version: 14.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012280-34-BEJanssen-Cilag International N.V.164
进行中（未招募）
1 期
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia - Lumiliximab in combination with FCR in the treatment of relapsed CRelapsed Chronic Lymphocytic Leukemia (CLL)MedDRA version: 9.1Level: LLTClassification code 10008956Term: Chronic lymphatic leukaemiaEUCTR2006-002987-24-FRBiogen Idec Ltd280